RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studiedAs a general reminder of pelareorep's evolving safety and effectiveness -
ONCY's Phase 2 Goblet study PDAC cohort involving pelareorep with atezolizumab resulted in the following data:
- Objective Response Rate (ORR) of 62% (54% confirmed by two or more scans)
- A Disease Control Rate (DCR) of 85%
Survival data: Evaluated based on 4 parameters including:
- Median duration of response was 5.7 months
- Median progression-free survival (PFS) was 7.2 months
- Interim 12-month survival rate was 46%
- Interim median overall survival (OS) was 10.6 months
This move by the FDA demonstrates that the Agency views pancreatic cancer as a significant (rare) disease with an unmet treatment need which appears responsive to checkpoint inhibitor therapy in combination with an immune stimulator.
https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/